连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察

Combined with Western Medicine Conventional Therapy in the Treatment of 63 Suspected Cases of Coronavirus Disease 2019

目的回顾性评价连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎(简称新冠肺炎)疑似病例的临床疗效及安全性。方法收集2020年1月1-27日在武汉科技大学附属华润武钢总医院就诊的新冠肺炎疑似患者病历101例,其中63例给予常规治疗(营养支持治疗、对症治疗、抗病毒及抗生素药物治疗)联合连花清瘟颗粒口服作为治疗组,38例仅给予常规治疗作为对照组。收集治疗10天后临床资料,比较两组主要症状(发热、咳嗽、乏力)消失率、发热持续时间、其他单项症状和体征消失率。结果治疗组发热、咳嗽、乏力症状消失率分别为86.7%、55.6%、82.5%,均明显高于对照组(分别为67.7%、30.6%、58.6%,P<0.05)。治疗组发热症状消失患者中位发热持续时间为6天,对照组为7天,两组比较差异无统计学意义(P=0.171)。治疗组气促和湿啰音体征消失率分别为68.2%和56.0%,均明显高于对照组(分别为20.0%和20.0%,P<0.05)。治疗组病情加重4例(6.4%)与对照组6例(15.8%)比较差异无统计学意义(P>0.05)。治疗组未见严重不良反应。结论连花清瘟颗粒联合西药常规治疗可明显改善新冠肺炎疑似病例发热、咳嗽、乏力、气促等症状,安全性好。

Objective To retrospectively evaluate clinical efficacy and safety of Lianhua Qingwen Granules(连花清瘟颗粒) combined with western medicine conventional therapy in the treatment of coronavirus disease 2019(COVID-19) suspected cases. Methods Medical records of 101 COVID-19 suspected patients admitted in CR & WISCO General Hospital Affiliated to Wuhan University of Science and Technology from January 1 to January 27, 2020 were retrospectively analyzed. Among them, 63 patients received conventional therapy in combination with Lianhua Qingwen Granules were taken as treatment group, and 38 patients received only conventional therapy were in the control group. Clinical data 10 days after the treatment were collected. A comparison between the 2 groups was performed in terms of disappearance rates of cardinal symptoms(fever, cough and weakness), duration of fever and disappearance rates of other individual symptoms and signs. Results The disappearance rates of fever, cough and weakness in the treatment group were 86.7%, 55.6% and 82.5%, respectively, which were higher than those in the control group(67.7%, 30.6% and 58.6%;P<0.05). In the treatment group, the median duration of fever was 6 days in patients with fever disappeared, and it was 7 days in the control group. There was no statistically significant difference between groups(P=0.171). The disappearance rates of short breath and moist crackles(68.2% and 56.0%) were higher than those in the control group(20.0% and 20.0%, P<0.05). There were 4 cases of aggravation in the treatment group(6.4%), while 6 cases in the control group(15.8%), without statistically significant difference(P>0.05). There were no obvious adverse reactions in the treatment group. Conclusion Lianhua Qingwen Granules combined with western medicine conventional therapy can significantly relieve symptoms like fever, cough, weakness and short breath in COVID-19 suspected cases with good safety.